Symbols

XERS

Xeris Biopharma·NASDAQ

--(--)

XERS fundamentals

XERS Q4 2025 Earnings

Xeris Biopharma (XERS) released its earnings on Mar 2, 2026: revenue was 83.43M (YoY +46.37%), beat estimates; EPS was 0.06 (YoY +300.00%), beat estimates.

Revenue / YoY

83.43M

+46.37%

EPS / YoY

0.06

+300.00%

Report date

Mar 2, 2026

XERS Earnings Call Summary for Q4,2025

Revenue Milestone: 2025 revenue up 44% to $292 million, achieving first full-year net income and $59.4 million adjusted EBITDA.
Recorlev Growth: Q4 revenue +100% YoY, patient base doubled to ~700; 2026 commercial expansion targets $1 billion peak by 2035.
Pipeline Catalyst: XP-8121 Phase III in H2 2026, with $1-3 billion peak sales potential for hypothyroidism treatment.
Financial Strength: 2026 guidance of $375-390 million revenue (+30% midpoint) with disciplined investment in R&D and commercial scale.
IP Confidence: Unchanged strategy for Recorlev despite ANDA litigation; strong IP portfolio (patents to 2040) supports long-term outlook.

Earnings

EPS

Revenue

Revenue & Expenses

XERS has released its 2025 Q4 earnings report, with revenue of 85.81M, reflecting a YoY change of 42.78%, and net profit of 11.08M, showing a YoY change of 316.72%. The Sankey diagram below clearly presents XERS's revenue sources and cost distribution.

Key Indicators

Xeris Biopharma (XERS) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Xeris Biopharma (XERS)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Xeris Biopharma (XERS)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Xeris Biopharma (XERS)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown